Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Multiple Sclerosis (MS) can be divided into three clinical phenotypes: relapsing remitting (RRMS), secondary progressive (SPMS) and primary progressive (PPMS). RRMS is characterized by episodic worsening followed by full or partial recovery, whereas SPMS and PPMS are characterized by steady accrual of disability.Progressive MS remains poorly understood and generally fails to respond to therapies that are effective in RRMS. This may be related to fundamental differences in the biology that underlies relapsing vs. progressive disease.Quantitative MRI techniques sensitive to evolution of new MS brain lesions and subtle changes within existing lesions will be obtained in people with MS. Characterizing repeated episodes of damage in existing MS lesions may reveal pathological distinctions between relapsing and progressive MS that are critical for understanding differences in the biology and evolution of these two components of MS. Assessment of injury and repair in repeat lesions may be critical for research, development and validation of drugs targeting processes important for the progressive (degenerative) stage of disease.The proposed project will investigate new potential imaging biomarkers of neurodegeneration and repair important for progression in MS, and integrate these biomarkers into the NeuroRx analysis environment, enabling NeuroRx to perform these analyses in future clinical trials.
NeuroRx Research Inc.
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects
The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.